Develops peptide-based drugs, including treatments for short bowel syndrome and obesity/metabolic disease.
Develops peptide-based drugs, including treatments for short bowel syndrome and obesity/metabolic disease.
Earns mainly through partners, which pay upfront and milestone fees and royalties on drugs Zealand discovered, such as Boehringer Ingelheim's survodutide, a weight-loss candidate, and a collaboration with Roche on the amylin analogue petrelintide. It keeps development of some rare-disease products for itself.
Moat: narrow (IP / patents, process know-how). Deep expertise in peptide drug design gives a pipeline of differentiated candidates and pharma partnerships.
Headquarters: Copenhagen, Denmark · Founded: 1998 · Employees: 481
Size Zealand Pharma A/S (ZEAL.CO) is a Denmark Health Care company (Biotechnology) with a market value of $2.16B, the 32nd largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 221.70 on 18 Nov 2026.
Performance Over six months the shares fell 30.3%, against -10.8% for the median peer and +6.3% for the Denmark market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue fell 49.8% over the last twelve months (peer median +4.1%); the operating margin is 46.2% (peer median -19.9%).
Valuation It trades at 7.2× forward earnings against a peer median of 38.4× (cheapest of 6).
Capital Return on invested capital runs 32.2 points above its cost of capital (7.1% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 4.60B | DKK 9.21B | DKK 62.7M | DKK 343M | DKK 104M |
| Revenue growth | — | +14,599% | -82% | +230% | — |
| Gross profit | DKK 4.56B | DKK 9.19B | DKK 29.0M | DKK 295M | DKK 73.3M |
| EBITDA | DKK 2.17B | DKK 7.18B | -DKK 1.24B | -DKK 533M | -DKK 749M |
| Net income | DKK 3.09B | DKK 6.46B | -DKK 1.08B | -DKK 704M | -DKK 966M |
| Free cash flow | -DKK 1.53B | DKK 6.50B | -DKK 941M | -DKK 437M | -DKK 954M |
| Capital expenditure | DKK 86.9M | DKK 69.1M | DKK 13.1M | DKK 23.7M | DKK 11.7M |
| Total debt | DKK 484M | DKK 406M | DKK 392M | DKK 200M | DKK 524M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zealand Pharma A/S ZEAL.CO | $2.16B | -30% | -50% | 46% | 7.2× | n/a |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 18.3× | 1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZEAL.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.5% | -7.2% | 10th highest of 21 |
| 6-month return | -30.3% | -10.8% | 4th lowest of 20 |
| Distance from 52-week high | -60.1% | -34.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | -49.8% | +4.1% | 5th lowest of 17 |
| Operating margin | 46.2% | -19.9% | 2nd highest of 15 |
| Forward P/E | 7.2× | 38.4× | cheapest of 6 |
| ROIC minus cost of capital | +32.2 pp | -11.6 pp | 3rd highest of 11 |
| EV / EBITDA | 0.8× | 9.8× | cheapest of 4 |
| Net debt / EBITDA | -6.0× | 1.4× | least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 7.2× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | n/a | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | n/a | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 126.7× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 38.4× | 13.4% | +44.5% |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 18.1× | 3.5% | +41.4% |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | n/a | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | n/a | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | n/a | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% | -3.8% |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 11.1× | -11.0% | +117.9% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |